Agreement - January 4, 2023
Orion and Amneal enter strategic partnership
Orion Corporation has signed a long-term license agreement with Amneal Pharmaceuticals to commercialize Amneal’s generic products in Orion territories. Under the terms of the agreement, Orion is granted exclusive licence to commercialize and sell Amneal’s generic products in most parts of Europe as well as in Australia and New Zealand. The initial portfolio will include […]
Biotech Business - October 4, 2022
Oncopeptides starts commercialization of Pepaxti in Europe
The company has submitted the AMNOG dossier to “The Federal Joint Committee” (G-BA) in Germany. This initiates the commercial launch of Pepaxti (melphalan flufenamide) and thus Germany will be the first market in Europe where the drug is launched, states the company in a press release. “The launch of Pepaxti in Germany is an important […]
New Market - September 6, 2022
Orientation Marketing opens office in Finland
Orientation Marketing has opened a new office in Espoo, Finland. The new office has been opened in order to serve the company’s growing client base in the Nordic and EU regions, it states in a press release. The new office will be managed through agency Co-Founder, Chris Lawson and Account Director, Anne Lawson. “With office […]
MedTech Business - August 19, 2022
Senzime receives FDA 510k-clearance
The company’s TetraGraph-system has now received FDA 510k-clearance for use in children with the disposable sensor TetraSens Pediatric. Senzime can thus broaden the indication for TetraGraph to also monitor infants and young children who have received muscle paralyzing drugs as part of anesthesia, the company states. Currently sold in 29 countries Senzime’s system for monitoring […]
New Market - August 10, 2022
AstraZeneca’s Enhertu approved in the US
AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy. Enhertu is a specifically […]
New Market - June 21, 2022
NorthX Biologics expands to cell therapy
NorthX Biologics is expanding into cell therapy manufacturing at its existing GMP-facility, as well as in premises at the Karolinska University Hospital campus in Stockholm. This initiative is part of NorthX’s Innovation Hub, an Innovation Track designed to provide development and GMP-manufacturing services to the next generation of drug development companies and innovative research groups […]
